Yu Tung Lo1,2, Ya Lyn Samantha Ang3,4, Valerie Shiwen Yang5,6, Dave Thevandiran Kanavathy4, Sai Liang3, Lester Lee3,4,7. 1. Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore. yutung.lo@mohh.com.sg. 2. Department of Neurosurgery, Outram Road, Singapore, 169608, Singapore. yutung.lo@mohh.com.sg. 3. Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore. 4. Department of Neurosurgery, Outram Road, Singapore, 169608, Singapore. 5. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. 6. Translational Precision Oncology Lab, Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore. 7. Duke-NUS Medical School, Singapore, Singapore.
Abstract
PURPOSE: Central nervous system lymphomas (CNSL) can present with motor and non-motor symptoms. In many central nervous system tumors, motor deficits are associated with significant morbidity and functional impairment, and correlate with worse prognosis. CNSLs however, often exhibit remarkable response to chemotherapy and radiotherapy with corresponding symptom improvement. We investigate the survival outcomes and trajectories of motor and functional recovery in a cohort of patients presenting with and without initial motor deficits. METHODS: Patients who underwent biopsy and with a histologically confirmed CNSL between 2008 and 2019 were retrospectively identified. Baseline demographic variables, comorbidities, presenting symptoms, histological type, neuroimaging features (location and number of lesions), and treatment administered (pre- and post-operative steroid use and chemotherapy regime) were recorded. Dates of death were obtained from the National Registry of Births and Deaths. Motor power and performance status at admission, 1 month and 6 months were determined. RESULTS: We identified 119 patients, of whom 34% presented with focal motor deficits. The median overall survival (OS) was 26.6 months. Those with focal motor deficits had longer OS (median 42.4 months) than those without (median 23.3 months; p = 0.047). In multivariate Cox analysis, age (HR 1.04 per year; p = 0.003), CCI (HR 1.31 per point; p < 0.001), leptomeningeal/ependymal involvement (HR 2.53; p = 0.016), thalamus involvement (HR 0.34; p = 0.019), neutrophil:lymphocyte ratio (HR 1.06 per point; p = 0.034), positive HIV status (HR 5.31; p = 0.003), preoperative steroids use (HR 0.49; p = 0.018), postoperative high-dose steroids (HR 0.26; p < 0.001) and postoperative low-dose steroids (HR 0.28; p = 0.010) were significant predictors of OS. By one month, 43% of surviving patients had full power, increasing to 61% by six months. CONCLUSION: A significant proportion of patients with initial motor deficits recovered in motor strength by six months. In our population, those presenting with motor deficits had paradoxically better overall survival.
PURPOSE:Central nervous system lymphomas (CNSL) can present with motor and non-motor symptoms. In many central nervous system tumors, motor deficits are associated with significant morbidity and functional impairment, and correlate with worse prognosis. CNSLs however, often exhibit remarkable response to chemotherapy and radiotherapy with corresponding symptom improvement. We investigate the survival outcomes and trajectories of motor and functional recovery in a cohort of patients presenting with and without initial motor deficits. METHODS:Patients who underwent biopsy and with a histologically confirmed CNSL between 2008 and 2019 were retrospectively identified. Baseline demographic variables, comorbidities, presenting symptoms, histological type, neuroimaging features (location and number of lesions), and treatment administered (pre- and post-operative steroid use and chemotherapy regime) were recorded. Dates of death were obtained from the National Registry of Births and Deaths. Motor power and performance status at admission, 1 month and 6 months were determined. RESULTS: We identified 119 patients, of whom 34% presented with focal motor deficits. The median overall survival (OS) was 26.6 months. Those with focal motor deficits had longer OS (median 42.4 months) than those without (median 23.3 months; p = 0.047). In multivariate Cox analysis, age (HR 1.04 per year; p = 0.003), CCI (HR 1.31 per point; p < 0.001), leptomeningeal/ependymal involvement (HR 2.53; p = 0.016), thalamus involvement (HR 0.34; p = 0.019), neutrophil:lymphocyte ratio (HR 1.06 per point; p = 0.034), positive HIV status (HR 5.31; p = 0.003), preoperative steroids use (HR 0.49; p = 0.018), postoperative high-dose steroids (HR 0.26; p < 0.001) and postoperative low-dose steroids (HR 0.28; p = 0.010) were significant predictors of OS. By one month, 43% of surviving patients had full power, increasing to 61% by six months. CONCLUSION: A significant proportion of patients with initial motor deficits recovered in motor strength by six months. In our population, those presenting with motor deficits had paradoxically better overall survival.
Entities:
Keywords:
Brain biopsy; Lymphoma; Motor recovery; PCNSL; Prognosis
Authors: Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: A J M Ferreri; M Reni; F Pasini; A Calderoni; U Tirelli; A Pivnik; G M Aondio; F Ferrarese; H Gomez; M Ponzoni; B Borisch; F Berger; C Chassagne; P Iuzzolino; A Carbone; J Weis; E Pedrinis; T Motta; A Jouvet; T Barbui; F Cavalli; J Y Blay Journal: Neurology Date: 2002-05-28 Impact factor: 9.910